Nat Commun｜姜、蒜、芦荟、柠檬等植物纳米颗粒能调节肠道菌群代谢 ...
研究人员从常见的姜、蒜、芦荟和柠檬中提取出了植物源纳米颗粒（PNP），并发现其包含Nano10和ELN两种不同类型。体外和体内实验均表明，PNP能够被肠道细菌摄取。在众多的肠道细菌中，Lachnospiraceae、Bacteroidaceae等细菌家族在摄取PNP的过程中表现得尤为活跃，是主要的摄取菌。而且，PNP的摄取效率并非一成不变，它会受到PNP类型、植物来源以及肠道微环境等多种因素的影响 ...
腾讯网26 天
Cell子刊：浙江大学蔡志坚团队发现克服抗PD-1治疗耐药的新靶点
TEV PD-L1 有助于 αPD-1 治疗耐药； UBE4A 介导的 PD-L1 泛素化诱导细胞外囊泡对 PD-L1 的分选； 来自肿瘤细胞的 MFGE8 通过激活自身的 α v 整合素信号上调 ...
Targeted Oncology13 小时
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
STAT28 天
Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of ...
“I think that the anti-PD-1 or PD-L1 and VEGF concept can be a very broad, pan-tumor platform: the next-generation checkpoint modulator.” Experts told STAT there’s been a surge of interest ...
7MRUS : Merus Shares Are Up Today: What's Going On?
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug ...
Pharmabiz1 天
Innovent receives second fast track designation from US FDA for IBI363 in squamous non ...
San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...
AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
AIM ImmunoTech (AIM) announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM’s ...